Highlights and Quick Summary
- EBIT for the quarter ending September 30, 2022 was $-129 Million (a 61.04% increase compared to previous quarter)
- Year-over-year quarterly EBIT decreased by -22.04%
- Annual EBIT for 2021 was $-1.15 Billion (a 21.53% increase from previous year)
- Annual EBIT for 2020 was $-949 Million (a 78.22% increase from previous year)
- Annual EBIT for 2019 was $-532 Million (a 189.93% increase from previous year)
- Twelve month EBIT ending September 30, 2022 was $-549 Million (a -3.58% decrease compared to previous quarter)
- Twelve month trailing EBIT decreased by -4.86% year-over-year
Trailing EBIT for the last four month:
30 Sep '22 | 30 Jun '22 | 31 Mar '22 | 31 Dec '21 |
---|---|---|---|
$-549 Million | $-569 Million | $-583 Million | $-577 Million |
Visit stockrow.com/BBIO
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical EBIT of BridgeBio Pharma, Inc.
Most recent EBITof BBIO including historical data for past 10 years.Interactive Chart of EBIT of BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. EBIT for the past 10 Years (both Annual and Quarterly)
(All values are in $ million)
Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
---|---|---|---|---|---|
2022 | – | $-129.12 | $-80.18 | $-173.68 | – |
2021 | $-165.61 | $-149.5 | $-94.02 | $-167.5 | $-1,153.26 |
2020 | $-127.49 | $-119.94 | $-124.57 | $-102.49 | $-948.96 |
2019 | $-78.64 | $-54.53 | $-69.32 | $-63.75 | $-532.48 |
2018 | – | – | – | $-41.46 | $-183.66 |
2017 | – | – | – | – | $-87.72 |
Business Profile of BridgeBio Pharma, Inc.
Sector: Healthcare
Industry: Biotechnology